Intravitreal Bevacizumab (Avastin) in the Treatment of Proliferative Diabetic Retinopathy
Top Cited Papers
- 31 October 2006
- journal article
- case report
- Published by Elsevier BV in Ophthalmology
- Vol. 113 (10), 1695-1705.e6
- https://doi.org/10.1016/j.ophtha.2006.05.064
Abstract
No abstract availableThis publication has 21 references indexed in Scilit:
- Intravitreal Bevacizumab (Avastin) for Neovascular Age-Related Macular DegenerationOphthalmology, 2006
- Vitreous Levels of Pigment Epithelium–Derived Factor and Vascular Endothelial Growth Factor Are Related to Diabetic Macular EdemaOphthalmology, 2006
- Changes in Retinal Neovascularization after Pegaptanib (Macugen) Therapy in Diabetic IndividualsOphthalmology, 2006
- A Phase II Randomized Double-Masked Trial of Pegaptanib, an Anti–Vascular Endothelial Growth Factor Aptamer, for Diabetic Macular EdemaOphthalmology, 2005
- Inhibitors of Ocular NeovascularizationJAMA, 2005
- Quantifying alterations of macular thickness before and after panretinal photocoagulation in patients with severe diabetic retinopathy and good visionOphthalmology, 2003
- VEGF164-mediated Inflammation Is Required for Pathological, but Not Physiological, Ischemia-induced Retinal NeovascularizationThe Journal of Experimental Medicine, 2003
- Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured fab in complex with antigenJournal of Molecular Biology, 1999
- Comparisons of the Intraocular Tissue Distribution, Pharmacokinetics, and Safety of 125I-Labeled Full-Length and Fab Antibodies in Rhesus Monkeys Following Intravitreal AdministrationToxicologic Pathology, 1999
- Tumor Angiogenesis: Therapeutic ImplicationsThe New England Journal of Medicine, 1971